Cargando…

CD56和(或)CD117表达在以硼替佐米为基础一线治疗的初诊多发性骨髓瘤患者中的预后意义

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342872/
https://www.ncbi.nlm.nih.gov/pubmed/31495142
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.08.016
_version_ 1783555614957371392
collection PubMed
description
format Online
Article
Text
id pubmed-7342872
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73428722020-07-16 CD56和(或)CD117表达在以硼替佐米为基础一线治疗的初诊多发性骨髓瘤患者中的预后意义 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2019-08 /pmc/articles/PMC7342872/ /pubmed/31495142 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.08.016 Text en 2019年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 短篇论著
CD56和(或)CD117表达在以硼替佐米为基础一线治疗的初诊多发性骨髓瘤患者中的预后意义
title CD56和(或)CD117表达在以硼替佐米为基础一线治疗的初诊多发性骨髓瘤患者中的预后意义
title_full CD56和(或)CD117表达在以硼替佐米为基础一线治疗的初诊多发性骨髓瘤患者中的预后意义
title_fullStr CD56和(或)CD117表达在以硼替佐米为基础一线治疗的初诊多发性骨髓瘤患者中的预后意义
title_full_unstemmed CD56和(或)CD117表达在以硼替佐米为基础一线治疗的初诊多发性骨髓瘤患者中的预后意义
title_short CD56和(或)CD117表达在以硼替佐米为基础一线治疗的初诊多发性骨髓瘤患者中的预后意义
title_sort cd56和(或)cd117表达在以硼替佐米为基础一线治疗的初诊多发性骨髓瘤患者中的预后意义
topic 短篇论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342872/
https://www.ncbi.nlm.nih.gov/pubmed/31495142
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.08.016
work_keys_str_mv AT cd56héhuòcd117biǎodázàiyǐpéngtìzuǒmǐwèijīchǔyīxiànzhìliáodechūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngdeyùhòuyìyì
AT cd56héhuòcd117biǎodázàiyǐpéngtìzuǒmǐwèijīchǔyīxiànzhìliáodechūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngdeyùhòuyìyì
AT cd56héhuòcd117biǎodázàiyǐpéngtìzuǒmǐwèijīchǔyīxiànzhìliáodechūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngdeyùhòuyìyì
AT cd56héhuòcd117biǎodázàiyǐpéngtìzuǒmǐwèijīchǔyīxiànzhìliáodechūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngdeyùhòuyìyì
AT cd56héhuòcd117biǎodázàiyǐpéngtìzuǒmǐwèijīchǔyīxiànzhìliáodechūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngdeyùhòuyìyì
AT cd56héhuòcd117biǎodázàiyǐpéngtìzuǒmǐwèijīchǔyīxiànzhìliáodechūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngdeyùhòuyìyì
AT cd56héhuòcd117biǎodázàiyǐpéngtìzuǒmǐwèijīchǔyīxiànzhìliáodechūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngdeyùhòuyìyì
AT cd56héhuòcd117biǎodázàiyǐpéngtìzuǒmǐwèijīchǔyīxiànzhìliáodechūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngdeyùhòuyìyì
AT cd56héhuòcd117biǎodázàiyǐpéngtìzuǒmǐwèijīchǔyīxiànzhìliáodechūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngdeyùhòuyìyì
AT cd56héhuòcd117biǎodázàiyǐpéngtìzuǒmǐwèijīchǔyīxiànzhìliáodechūzhěnduōfāxìnggǔsuǐliúhuànzhězhōngdeyùhòuyìyì